Gb Sciences To Begin Dosage Study For Cannabinoid-Containing Drug For Treatment Of Parkinson's Disease

Gb Sciences, Inc. GBLX has selected the University of Lethbridge in Canada to complete a dose range study of Gb Sciences' patent-protected formulations in a rodent model of Parkinson's disease. The company plans on filing an investigational new drug application to begin first-in-human clinical trials as early as next year. As the second-most common neurodegenerative disease, the market for Parkinson's disease treatments is expected to grow to $8.8 billion by 2026.

Gb Sciences received U.S. Patent No. 10,653,640 in May 2020 for its proprietary cannabinoid-containing therapeutic mixtures for the treatment of PD. Animal studies conducted by the National Research Council of Canada found that Gb Sciences' PD formulations achieved statistically significant reductions in the PD-like motor symptoms associated with the loss of dopamine-producing neurons. Initial toxicity studies for these original PD formulas came back with no significant evidence of adverse effects.

Through GbS Global Biopharma, its wholly owned Canadian subsidiary, Gb Sciences has signed a contract with the University of Lethbridge, located in Alberta, Canada, to complete required rodent dose response studies. These important studies will determine the dose range of active ingredients that will be used in human trials and will identify potential side effects. These dose range studies are scheduled to begin next month.

"Our drug discovery process has identified ratio-specific mixtures of cannabinoids that achieved the statistically significant reduction of Parkinsonian movement symptoms in an animal model; thus establishing our proof-of-concept for this therapeutic program," stated Dr. Andrea Small-Howard, president and chief science officer of Gb Sciences. "Now, working with the University of Lethbridge, we are taking a major step forward by testing these cannabinoid ratio-specific formulations to establish the dose range for our first-in-human clinical trial."

Minimum Essential Mixtures

To create Gb Sciences' novel therapies, the company's goal is to identify 'minimum essential mixtures' that retain the efficacy of whole plant extracts, but with the manufacturing and quality control advantages of single ingredient pharmaceutical products. Gb Sciences uses its novel PhAROS (Phytomedical Analytics for Research Optimization at Scale) drug discovery engine's predictive capabilities, combined with rigorous high throughput screening of potential combinations of these plant-derived compounds in established cellular models of disease to determine which minimum essential mixtures from these plant-based materials may be therapeutically beneficial. These minimum essential mixtures are then validated and refined in animal models, in preparation for the first-in-human trial.

Related News